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Background: Triptans are effective for immediate relief of episodic cluster headache (CH) but do not reduce the
frequency of attacks. Intravenous bolus injection of corticosteroids like methylprednisolone (MP) has been reported
to decrease the frequency of CH attacks. We validated the prophylactic efficacy of MP pulse therapy by monitoring
CH recurrence over several years following treatment of six consecutive male patients (mean age: 38.8 years, range:
26–54 years) afflicted by frequent (often daily) CH attacks.
Findings: Total MP dose per infusion was 250–500 mg for five patients and 125 mg for the sixth (a diabetic). High-
dose MP was administered for 2 or 3 consecutive days in hospital for the first two patients treated. The next four
patients received a single bolus injection at presentation, and in some cases a second injection days later at an
outpatient clinic. The first two cases treated were also prescribed daily oral prednisolone for at most 6 months
while the latter four cases were not. The frequency of CH attacks was markedly reduced in all patients, with
intervals between attacks ranging from 4 to 23 months. We noted no apparent adverse events following MP
administration.
Conclusions: High-dose MP therapy reduced CH attack frequency and improved patient quality of life.
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Subcutaneous injection of sumatriptan succinate is an
effective treatment for the immediate relief of episodic
cluster headache (CH) but does not reduce the fre-
quency of future attacks. Prolonged or frequent attacks
and associated treatment visits can greatly impair patient
quality of life. In Japan, self-administration of sumatrip-
tan succinate was approved in February 2008, and this
change has greatly reduced emergency visits and hospital
admissions due to CH. However, patients with chronic
CH may still require frequent hospital visits, taxing re-
sources and increasing personal medical expenses. To
reduce the frequency of attacks, guidelines from the
Japanese Society of Neurology recommend calcium chan-
nel blockers (verapamil, lomerizine hydrochloride), gluco-
corticoids, or ergotamine tartrate. Calcium channel
blockers are often useful in the prevention of migraine
headache, but are less effective in the prevention of cluster
headaches. Oral glucocorticoids are often effective against* Correspondence: kawada@kyokuto.or.jp
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in any medium, provided the original work is pCH: however, the side effects may be intolerable for some
patients. Several recent studies have reported the benefits
of intravenous bolus injection of methylprednisolone
(MP) for episodic CH. In this case series, we evaluated the
efficacy of this treatment for Japanese male patients ex-
periencing frequent CH attacks.
Material and methods
This case series reports the clinical results for six con-
secutive male patients with frequent episodic CH treated
by bolus injection of MP. MP was administered by intra-
venous (i.v.) drip over two hours up to a total dose of
250–500 mg per infusion with the exception of a dia-
betic patient who was administered 125 mg MP per in-
fusion. If the patient experienced a severe CH attack at
presentation, they were injected subcutaneously with su-
matriptan succinate before MP injection. The first two
cases in the series were admitted to hospital and re-
ceived MP pulse therapy for 2 or 3 consecutive days as
inpatients. If CH was not suppressed, a second course of
pulse therapy was administered after a four-day interval.
The latter four patients could not be admitted due toan Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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istered a single bolus MP injection and in some cases, a
second bolus injection at a later time in an outpatient
department (Table 1). This study was approved by The
Ethics Committee of Okayama Kyokuto Hospital and in-
formed consent was obtained from all subjects prior to
the study.
Results
At presentation, all six patients reported daily CH at-
tacks that required subcutaneous injection of sumatrip-
tan succinate and (or) inhalation of pure oxygen. These
therapies were effective, but the frequent attacks ser-
iously disrupted quality of life. The MP pulse therapy
regimens used on initial presentation, the times of recur-
rence, and oral prednisolone regimens are presented in
Table. In all cases, CH attack frequency was markedly
reduced following MP therapy and no patient reported
severe CH for at least four months after treatment. Case
1 relapsed thrice and was treated as an inpatient except
on the fourth occasion. Case 2 reported no headache for
two days after the first trial of MP pulse administration
(one injection per day for three consecutive days): how-
ever, he suffered from severe headache again on the sixth
day of admission and was administered another series of
injections. Case 2 relapsed only twice, although 3 or 4
non-consecutive high-dose bolus injections were re-
quired on each recurrence. The other four cases wereTable 1 Cluster headache attacks and steroid theraphy




1 54 Male Initial presentation 250 mg (D
4 250 mg
4 250 mg (D
5 250 mg
2 33 Male Initial presentation 250 mg (D
23 250 mg (Days 1 and
11 500 mg (Days
3 33 Male Initial presentation 250 mg (Day 1) +
6 250 mg





5 49 Male Initial presentation 125 mg (Da
7 125 mg
6 26 Male Initial presentation 500 mg
11 500 mg
Day 1: the 1st day of MP injection during one CH attack.never hospitalized. Three of these four patients relapsed
only once (6, 7, and 11 months after initial treatment)
and were treated by a single bolus injection of MP each
time. Case 4 relapsed four times, but also required only
a single bolus injection each time, and each treatment
required only a half-day absence from work. We noted
no adverse events following steroid pulse therapy, such
as gastrointestinal bleeding or psychiatric symptoms,
and the diabetic patient (Case 5) demonstrated no loss
of glucose control.
Discussion
Cluster headaches afflict 0.07-0. 09% of the population,
and the incidence is 9.8 events/million person-years
Swanson et al. (1994). The prevalence of CH is 5–9
times higher in men, and indeed all patients in this case
series were men. Cluster headache is a rare disease but
symptom severity precludes placebo-controlled studies.
Therefore, therapeutic regimens are inconsistent across
institutions and countries. According to the Japanese
guidelines for chronic headache, triptans or oxygen in-
halation is the first-line therapy for acute CH attacks,
and most patients respond well to either treatment.
However, it is recommended that inhalation of 100%
oxygen be initiated within 10 minutes of attack onset,
making this treatment option impractical for patients
with unpredictable CH. Subcutaneous sumatriptan injec-
tion is effective and Japanese approval of self-injectionnisolone dose
enous)
Admission Prednisolone dose and duration
(daily oral)
ays 1 and 2) Yes 10 mg, 90 days
(Days 1–3) Yes none
ays 1 and 2) Yes 5 mg, 60 days
(Day 1) No 5 mg, 180 days
ays 1–3, 7–9) Yes 20 mg, 10 days
9) + 500 mg (Day 4) No 15 mg, 30 days
1, 7, 11, and 13) No 10 mg, 40 days
500 mg (Day 18) No none
(Day 1) No none
(Day 1) No none
(Day 1) No none
(Day 1) No none
(Day 1) No none
(Day 1) No none
ys 1 and 44) No none
(Day 1) No none
(Day 1) No none
(Day 1) No none
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Intranasal sumatriptan and oral zolmitriptan (intranasal
zolmitriptan is not yet approved in Japan) are also effect-
ive for patients that cannot self-inject sumatriptan. In-
tranasal lidocaine or cocaine is also effective but rarely
used in Japan.
During active CH periods, severe headaches occur al-
most daily, interfering with work or school and present-
ing patients with a significant financial burden for drugs
or oxygen. Prophylactic therapy would thus greatly im-
prove quality of life, relieve financial hardship, and save
medical resources. The guidelines from the Japanese
Society of Neurology recommend ergotamine, calcium-
channel blockers, or corticosteroids for prophylaxis at the
beginning of a cluster period, although the efficacy of
these treatments is highly variable. Double-blind trials
have demonstrated the effectiveness of verapamil, but
bradycardia and heart block are serious risks. Although
lomerizine has less severe cardiovascular side effects and
is useful for migraine, there is currently no evidence that
lomerizine is an effective prophylactic treatment for CH.
Moreover, there are no double-blind placebo-controlled
studies of corticosteroid efficacy: nonetheless, corticoste-
roids have been used for rapid CH control for more than
60 years Horton (1952). Oral and intravenous corti-
costeroids may be beneficial Ashkenazi & Schwedt (2011);
Shapiro (2005). For oral administration, daily 40–80 mg
prednisolone with gradual reduction over 10 days or lon-
ger is recommended Couch & Ziegler (1978).
There are few reports on the efficacy of intravenous
steroid infusion Reija et al. (1998); Cianchetti et al. (1998);
Mir et al. (2003); Antonaci et al. (2005). Reija et al. (1998)
reported a series of 18 episodic CH patients treated with
16 mg dexamethasone (i.v.) tapering off after 15 days. On
this cohort, 17 patients showed reduced CH attack fre-
quency Reija et al. (1998). Cianchetti et al. (1998) reported
a single case with chronic CH who showed no response to
two weeks of daily 100 mg prednisone but responded dra-
matically to single 500 mg doses of intravenous MP
Cianchetti et al. (1998). Mir et al. (2003) treated 14 epi-
sodic CH patients with 250 mg intravenous MP on three
consecutive days, followed by 90 mg oral prednisone
with gradual tapering over 4 weeks, and reported super-
ior results compared to previous treatments Mir et al.
(2003). Finally, Antonaci et al. (2005) treated 13 episodic
CH patients with 30 mg/kg intravenous MP on the
eighth day of the active CH period and reported signifi-
cantly reduced attack frequency in all patients, whereas
three patients experienced complete headache remission
Antonaci et al. (2005).
The therapeutic benefits of corticosteroids may stem,
at least in part, from anti-inflammatory effects because
inflammation may play an important role in the onset and
exacerbation of CH Hannerz (1991). Orbital phlebographyand gallium single photon emission computerized tomog-
raphy revealed inflammation in the cavernous sinus ipsi-
lateral to the CH pain side during the attack Gawel et al.
(1990); Hardebo & Ryberg (1989). Moreover, elevated
serum concentrations of some inflammatory mediators
such as haptoglobin, orosomucoid, and interleukin-I beta,
have been reported during CH attacks Hannerz (1991);
Martelletti et al. (1993). Several investigations have
reported elevated baseline plasma cortisol levels during
CH attacks Waldenlind et al. (1987); Leone et al. (1995);
Strittmatter et al. (1996). In addition to cortisol, testoster-
one and melatonin may also be linked to the pathogenesis
of CH Stillman (2006). Positron emission tomography re-
vealed hyperactivation in the gray matter of the ipsilateral
hypothalamus during the acute pain state May et al.
(1998); Sprenger et al. (2004). Hypothalamic activation
coupled with elevated serum cortisol suggests that epi-
sodic CH patients may have a dysfunctional hypothalamic-
pituitary-adrenal axis. Recently, hypothalamic deep brain
stimulation (hDBS) has been used effectively to treat
CH patients Magis et al. (2012). The therapeutic mech-
anism of hDBS may be similar to high-dose MP injection,
suppression of hypothalamic hyperactivity by negative
feedback.
High-dose MP injection may produce serious side ef-
fects, including infectious diseases resulting from im-
munosuppression, hypertension, and elevated blood
glucose: therefore, this treatment option should be used
with caution (particularly as outpatient therapy) in the
elderly or for patients with serious underlying diseases
such as diabetes. However, MP is far less invasive than
hDBS and so should be considered before hDBS. More-
over, younger patients and those without serious contra-
indication rarely exhibit serious side effects in response
to high-dose MP. Finally, MP pulse therapy can be ad-
ministered rapidly with little need for school or work ab-
sence. Thus, high-dose MP injection may be an optimal
treatment for otherwise healthy active CH patients.
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